jRCT ロゴ

臨床研究等提出・公開システム

Top

Japanese

Jan. 19, 2026

April. 06, 2026

jRCT2031250655

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Dose of MK-8507 and Multiple Once Weekly Dose of Islatravir/MK-8507
(MK-8591B) in Healthy Japanese Participants

A Clinical Study of Islatravir/MK-8507 (MK-8591B) in Healthy Japanese Participants

Yoshitsugu Hiroyuki

MSD K.K.

KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan

+81-3-6272-1957

msdjrct@msd.com

MSDJRCT inquiry mailbox

MSD K.K.

KITANOMARU SQUARE,1-13-12,Kudan-kita,Chiyoda-ku,Tokyo 102-8667,Japan

+81-3-6272-1957

msdjrct@msd.com

Recruiting

Mar. 26, 2026

April. 03, 2026
24

Interventional

randomized controlled trial

double blind

placebo control

parallel assignment

treatment purpose

Healthy male and female participants between the ages of 18 and 55 years

Has a history of clinically significant abnormalities or diseases

18age old over
55age old under

Both

HIV infection

Single dose of MK-8507 100, 200 and 400 mg or placebo
Multiple weekly doses of MK-8591B (Islatravir/MK-8507) 2 mg/200 mg or placebo

Safety (Adverse events, discontinuation of study intervention due to adverse events), Pharmacokinetics

MSD K.K.
Houeikai Institutional Review Board
3-28-3, Ikebukuro, Toshima-ku, Tokyo

+81-3-5396-4530

Approval

Feb. 12, 2026

Yes

https://engagezone.msd.com/

none

History of Changes

No Publication date
2 April. 06, 2026 (this page) Changes
1 Jan. 19, 2026 Detail